A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women
Condition: Respiratory Syncytial Virus Infections
MeSH terms: Respiratory Syncytial Virus Infections
Intervention: RSVPreF3 formulation 3; RSVPreF3 formulation 2; Boostrix-ex-US; Boostrix-US; Placebo
Intervention description: One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.; One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.; One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.; One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.; One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
Phase: Phase 2
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking description: Data will be collected in an observer-blind manner. In an observer-blind study, the subject and the site and sponsor personnel involved in the clinical evaluation of the subjects are blinded while other study personnel may be aware of the treatment assignment. By observer-blind, it is meant that during the course of the study, the vaccine(s) recipient and those responsible for the evaluation of any study endpoint (e.g. safety, reactogenicity) will all be unaware of which vaccines were administered.
Enrollment: 509.0
Sex: Female
Minimum age: 18 Years
Maximum age: 45 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The purpose of this study is to evaluate the safety, ability of GSK Biologicals'
      investigational RSV maternal vaccine (RSVPreF3) to generate an immune response and the degree
      to which the vaccine can cause side effects, when administered alone and in combination with
      Boostrix vaccine in healthy non-pregnant women 18-45 years of age. Two dose levels of
      RSVPreF3 and 2 Boostrix [Diphtheria, Tetanus and acellular Pertussis (dTpa) vaccine]
      formulations (US and ex-US) will be evaluated. A 2nd dose of RSVPreF3 will be administered in
      an extension of the study to assess the durability of the immune response after the first
      dose vaccination, and to assess the safety and immunogenicity following a second dose
      vaccination of the RSVPreF3 maternal vaccine.
    

Eligibility criteria:

        Inclusion Criteria:

        Primary study

          -  Subjects who, in the opinion of the investigator, can and will comply with the
             requirements of the protocol.

          -  Written or witnessed/thumb printed informed consent obtained from the subject prior to
             performance of any study specific procedure.

          -  Healthy female subjects; as established by medical history and clinical examination,
             aged 18 to 45 years at the time of the 1st vaccination;

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

               -  has practiced adequate contraception for 30 days prior to primary vaccination,
                  and

               -  has a negative pregnancy test on the day of primary vaccination, and

               -  has agreed to continue adequate contraception for 90 days after completion of the
                  vaccination.

          -  No local condition precluding injection in both left and right deltoid muscles.

        Extension study

          -  Completed primary study and received 1st dose of a study vaccine.

          -  Written or witnessed/thumb printed informed consent obtained from the subject prior to
             performance of any study specific procedure to the study extension.

        All subjects must satisfy ALL the following criteria:

          -  Subjects who can and will comply with the requirements of the protocol.

          -  Female subjects remain healthy; as established by medical history and clinical
             examination, aged 18 to 45 years at the time of the 1st vaccination;

          -  Female subjects of childbearing potential are eligible for the extension, if the
             subject:

               -  has practiced adequate contraception for 30 days prior to 2nd vaccination

               -  has a negative pregnancy test with results available on the day of 2nd
                  vaccination

               -  has agreed to continue adequate contraception for 90 days after completion of the
                  2nd vaccination.

        Exclusion Criteria:

        Primary study

        Medical conditions

          -  History of any reaction/hypersensitivity likely to be exacerbated by any vaccines'
             component;

          -  Any confirmed/suspected immunosuppressive/immunodeficient condition, based on medical
             history and physical examination;

          -  Hypersensitivity to latex;

          -  Major congenital defects;

          -  Acute/chronic clinically significant pulmonary, cardiovascular, hepatic/renal
             functional abnormality;

          -  Significant/uncontrolled psychiatric illness;

          -  Recurrent history/uncontrolled neurological disorders/seizures;

          -  Documented HIV-positive subject;

          -  History of/current autoimmune disease;

          -  Body mass index (BMI)>40 kg/m^2;

          -  Any clinically significant hematological parameter and/or biochemical laboratory
             abnormality.

          -  Any other clinical condition that might pose additional risk to the subject due to
             participation in the study.

        Prior/Concomitant therapy

          -  Use of any investigational/non-registered product other than the study vaccines during
             the period starting 30 days before 1st vaccination, or planned use during the study;

          -  Administration of long-acting immune-modifying drugs at any time during the study;

          -  Administration of immunoglobulins and/or any blood products/plasma derivatives during
             the period starting 3 months before the 1st vaccination or planned administration
             during the study;

          -  Chronic administration of immunosuppressants/other immune-modifying drugs during the
             period starting 3 months prior to 1st vaccine dose(s). For corticosteroids, this will
             mean prednisone ≥5 mg/day, or equivalent. Inhaled and topical steroids are allowed;

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within the period starting 30 days before and ending 30 days after study 1st
             vaccination, with the exception of any licensed influenza vaccine which may be
             administered ≥ 15 days before/after study vaccination;

          -  Administration of a vaccine containing diphtheria, tetanus/pertussis
             antigens/diphtheria and tetanus toxoids within the previous 5 years;

          -  Previous experimental vaccination against RSV;

        Prior/Concurrent clinical study experience • Concurrently participating in another clinical
        study, at any time during the study, in which the subject has been/will be exposed to an
        investigational/a non-investigational vaccine/product;

        Other exclusions

          -  Pregnant/lactating female;

          -  Female planning to become pregnant/planning to discontinue contraceptive precautions;

          -  History of alcoholism, drug abuse and/or use disorder within the past 2 years;

          -  Any study personnel/their immediate dependents, family/household members.

        Extension study

        Medical conditions

          -  History of any reaction/hypersensitivity likely to be exacerbated by any component of
             the vaccines;

          -  Any confirmed/suspected immunosuppressive/immunodeficient condition, based on medical
             history and physical examination;

          -  Hypersensitivity to latex;

          -  Acute/chronic clinically significant pulmonary, cardiovascular, hepatic/renal
             functional abnormality;

          -  Significant/uncontrolled psychiatric illness;

          -  Recurrent history/uncontrolled neurological disorders/seizures;

          -  Documented HIV-positive subject;

          -  History of/current autoimmune disease;

          -  BMI>40 kg/m^2;

          -  Participants who experienced any SAE judged to be possibly or probably related to 1st
             dose of RSVPreF3, including hypersensitivity reactions.

          -  Any other clinical condition that might pose additional risk to the subject due to
             participation in the study.

        Prior/Concomitant therapy

          -  Use of any investigational/non-registered product other than the study vaccines during
             the period starting 30 days before the 2nd vaccination, or planned use during the
             6-month study extension;

          -  Administration of long-acting immune-modifying drugs at any time during the study;

          -  Administration of immunoglobulins and/or any blood products/plasma derivatives during
             the period starting 3 months before the 1st dose of study vaccines/planned
             administration during the study;

          -  Chronic administration of immunosuppressants or other immune-modifying drugs during
             the starting 3 months prior to the 1st vaccine dose(s). For corticosteroids, this will
             mean prednisone ≥5 mg/day, or equivalent. Inhaled and topical steroids are allowed;

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within the period starting 30 days before and ending 30 days after study 2nd
             vaccination, with the exception of any licensed influenza vaccine which may be
             administered ≥ 15 days before/after study vaccination.

        Prior/Concurrent clinical study experience

        • Concurrently participating in another clinical study, at any time during the study, in
        which the subject has been/will be exposed to an investigational/a non-investigational
        vaccine/product;

        Other exclusions

          -  Pregnant/lactating female at the time of Visit 4;

          -  Female planning to become pregnant/planning to discontinue contraceptive precautions;

          -  History of alcoholism, drug abuse and/or use disorder within the past 2 years;

          -  Any study personnel/their immediate dependents, family/household members.